Why Healthcare Reimbursement Kills Software

Modern medicine is obsessed with the existential; digital software is concerned with the relational. The collision of these two worldviews explains why digital health has produced so many press releases and so little actual transformation.

In healthcare regulatory parlance, an intervention is deemed relevant only if it demonstrates an existential impact: clinical trial evidence showing a statistically significant mitigation of a specific disease marker or mortality rate. This standard was forged in the era of synthetic molecules and titanium hip implants, where a device or drug acts directly upon the human organism.

Software does not work that way. A medical device is an isolated physical object; a digital product is a node in an evolving social network.

The Yahoo error of clinical classification

When healthcare systems evaluate digital therapeutics, they commit what might be called the “Yahoo error” of 1995.

In the early days of the web, Yahoo attempted to organise the internet by manually cataloguing websites into hierarchical taxonomies. It failed because the complexity of the web quickly outstripped any static category system. Google triumphed not by categorising sites better, but by analyzing the topology of relationships—who links to whom, and where users actually navigate.

Traditional medicine remains trapped in the Yahoo paradigm. It categorises human suffering into rigid ICD codes, assigns each code an approved clinical pathway, and demands that software slot into these pre-existing boxes like an interactive brochure.

Yet the primary power of digital technology in healthcare is not to deliver clinical content down a fixed pipeline. It is to dynamically reconfigure the relationships between patients, clinicians, and health data.

Three systemic contradictions

By treating software as if it were a chemical compound, modern reimbursement regimes systematically strangle digital products:

1. Reimbursing the feature, ignoring the network. Regulators are willing to pay for the single algorithm that calculates an insulin dose, but refuse to compensate the communicative infrastructure that ensures the patient actually uses it. In software, isolated utility is worthless without user engagement; in regulatory dogma, user engagement is viewed as superfluous luxury.
2. The tyranny of the randomized controlled trial. An RCT evaluates a static intervention over years. A good software product evolves weekly based on telemetry and user behavioural patterns. Forcing a digital platform through a drug-style clinical trial freezes its codebase in amber, preventing the rapid iteration upon which modern software efficacy depends.
3. The misaligned incentives of clinical labour. Healthcare policy assumes that if you build a digital network, doctors will eagerly populate it. But human participation in digital networks is fundamentally non-linear: in almost every online community, 90% of users consume, 9% curate, and only 1% create. Expecting already exhausted physicians to become active content contributors without direct financial and operational upside is a bureaucratic fantasy.

Toward a relational health economy

If digital healthcare is ever to fulfil its promise, the reimbursement model must move from paying for isolated evidence to paying for systemic outcomes.

We do not need more prescription apps that mimic paper medical diaries. We need regulatory frameworks that recognise that software creates value through network effects, operational fluidity, and continuous feedback loops. Until health insurers stop treating software like a digital pill, they will continue paying for technology that nobody uses.